Renal dialysis

Rockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2021 Conference

Retrieved on: 
Tuesday, January 5, 2021
Chemistry, Physical sciences, Clinical medicine, Mineral deficiencies, Membrane technology, Rockwell Medical, Renal dialysis, Anemias, Transfusion medicine, Rockwell, Iron-deficiency anemia, Iron

WIXOM, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (Rockwell Medical or the Company), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, today announced the Rockwell Medical executive management team will record a presentation at H.C. Wainwright BioConnect 2021 Conference.

Key Points: 
  • WIXOM, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (Rockwell Medical or the Company), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, today announced the Rockwell Medical executive management team will record a presentation at H.C. Wainwright BioConnect 2021 Conference.
  • ET and will be archived for 30 days thereafter, via the Companys website at www.rockwellmed.com , under the Investors section.
  • Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.
  • Triferic is a registered trademark of Rockwell Medical, Inc. Triferic AVNU is pending with the U.S. Patent and Trademark Office.

Insights on the Hemodialysis Equipment Market 2020-2024: COVID-19 Industry Analysis, Market Trends, Market Growth, Opportunities and Forecast 2024 - Technavio

Retrieved on: 
Monday, January 4, 2021
Health, Nursing, Medical devices, Medicine, Clinical medicine, Renal dialysis, Membrane technology, Medical specialties, Nephrology, Home hemodialysis, Hemodialysis, Dialysis

The hemodialysis equipment market share growth by the in-center hemodialysis segment will be faster than the growth of the market by the home hemodialysis segment.

Key Points: 
  • The hemodialysis equipment market share growth by the in-center hemodialysis segment will be faster than the growth of the market by the home hemodialysis segment.
  • Europe was the largest hemodialysis equipment market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period.
  • The adoption of advanced hemodialysis equipment, increasing prevalence of kidney diseases, the growing healthcare expenditure, and favorable reimbursement will significantly drive hemodialysis equipment market growth in this region over the forecast period.
  • Market growth in this region will be slower than the growth of the market in Asia.

Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus

Retrieved on: 
Monday, December 28, 2020
Membrane technology, Medicine, Renal dialysis, Hemodialysis, Dialysis

Cara has requested Priority Review for the NDA which, if granted, could result in a six-month review process.

Key Points: 
  • Cara has requested Priority Review for the NDA which, if granted, could result in a six-month review process.
  • The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing.
  • The NDA submission for KORSUVA Injection marks a significant milestone for Cara and for hemodialysis patients who suffer from intractable pruritus, said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.
  • Pisoni RL, et al.Pruritus in hemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study.Nephrol Dial Transplant.2006; 21:3495-3505.

World Peritoneal Dialysis Market Segmentation & Impact Analysis 2020

Retrieved on: 
Wednesday, December 23, 2020
Medicine, Clinical medicine, Membrane technology, Branches of biology, Renal dialysis, Detoxification, Dialysis, Peritoneal dialysis, Abdomen, Peritoneum, Kidney, PD

DUBLIN, Dec. 23, 2020 /PRNewswire/ -- The "Peritoneal Dialysis Market Share, Size and Growth, By Type, By End-User By Product And Segment Forecasts, 2016-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 23, 2020 /PRNewswire/ -- The "Peritoneal Dialysis Market Share, Size and Growth, By Type, By End-User By Product And Segment Forecasts, 2016-2026" report has been added to ResearchAndMarkets.com's offering.
  • The Peritoneal Dialysis Market is estimated to reach USD 5.58 Billion by 2027.
  • Peritoneal dialysis (PD) is a method of dialysis that uses dialysis solution and the inner lining of the abdomen to drain blood when the kidneys are not functioning efficiently.
  • Peritoneal dialysis is the cleansing of blood and the elimination of extra fluids by using the peritoneal membrane, the body's natural filter.

Global Peritoneal Dialysis Market Share, Size and Growth Forecasts to 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 18, 2020
Medical devices, Health, Medicine, Clinical medicine, Branches of biology, Membrane technology, Renal dialysis, Nephrology, Organ failure, Peritoneal dialysis, Dialysis, Kidney

The "Peritoneal Dialysis Market Share, Size and Growth, By Type, By End-User By Product And Segment Forecasts, 2016-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peritoneal Dialysis Market Share, Size and Growth, By Type, By End-User By Product And Segment Forecasts, 2016-2026" report has been added to ResearchAndMarkets.com's offering.
  • Increasing occurrences of renal failure due to hypertension, stress, and diabetes mellitus globally, are the major factors influencing the market growth.
  • The Peritoneal Dialysis Market is estimated to reach USD 5.58 Billion by 2027.
  • Peritoneal dialysis (PD) is a method of dialysis that uses dialysis solution and the inner lining of the abdomen to drain blood when the kidneys are not functioning efficiently.

$116 Billion Hemodialysis Market - Global Opportunity Analysis and Industry Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 9, 2020
Retail, Other Retail, Membrane technology, Medicine, Renal dialysis, Hemodialysis, Dialysis

The "Hemodialysis Market by Product & Service, Type, End User - Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hemodialysis Market by Product & Service, Type, End User - Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The Global Hemodialysis Market was valued at USD 78.30 billion in 2019 and is estimated to reach USD 116.66 billion by 2030, expanding at a CAGR of 3.60% during the forecast period, from 2020 to 2030.
  • Market Segmentations and Scope of the Study:
    The hemodialysis market has been divided in terms of product & service, type, end user, and geography.
  • Therefore, the region accounts for a dominate share of the global hemodialysis market.

Medtronic Launches the First and Only Pediatric and Neonatal Acute Dialysis Machine in the U.S.

Retrieved on: 
Tuesday, December 8, 2020
Medicine, Clinical medicine, Membrane technology, Medical specialties, Kidney diseases, Organ failure, Acute kidney injury, Renal dialysis, Hemofiltration, Dialysis, Hemodialysis, Renal replacement therapy

The first of its kind Carpediem system is indicated for use in acute kidney injury or fluid overloaded patients requiring hemodialysis or hemofiltration therapy.

Key Points: 
  • The first of its kind Carpediem system is indicated for use in acute kidney injury or fluid overloaded patients requiring hemodialysis or hemofiltration therapy.
  • The mortality rate for neonates with acute kidney injury has been reported to be as high as 60 percent.
  • "This new system is designed specifically for these patients which enables increased precision of neonatal CRRT treatment and, potentially, reduces these risks.
  • Developing a neonatal acute kidney injury research definition: a report from the NIDDK neonatal AKI workshop.

Stanford Surgeon Venita Chandra Joins Alucent Biomedical Scientific Advisory Board as Company Enters Arteriovenous Fistula Market

Retrieved on: 
Tuesday, December 8, 2020
Medical devices, Health, Surgery, Pharmaceutical, Cardiology, Biotechnology, Medicine, Clinical medicine, Renal dialysis, AVF, Arteriovenous fistula, Arteriovenous, Fistula, NVS, Avera Health, Hemodialysis, Cimino fistula

Alucent Biomedical , a privately held medical technology company founded to transform the way vascular disease is treated, today announced Venita Chandra, M.D.

Key Points: 
  • Alucent Biomedical , a privately held medical technology company founded to transform the way vascular disease is treated, today announced Venita Chandra, M.D.
  • The company announced today it will also seek to adapt the technology for another use, the maturation and preservation of arteriovenous fistula (AVF) for hemodialysis (HD).
  • Applying the treatment at fistula creation has facilitated maturation and the promotion of outward remodeling of the AVF, Dr. Chandra said.
  • Alucent was founded by Avera Health to develop and market products using Alucent Natural Vascular Scaffolding (Alucent NVS) technology.

South and Central America Portable and Wearable Dialysis Devices Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product Type ; End users, and Country

Retrieved on: 
Tuesday, November 24, 2020
Medicine, Clinical medicine, Medical specialties, Renal dialysis, Membrane technology, Nephrology, Dialysis, Hemodialysis, End Stage Renal Disease Program, Peritoneal dialysis, Kidney failure, Northwest Kidney Centers

The growth of the South and Central America and portable and wearable dialysis devices market is attributed to the growing prevalence of chronic kidney conditions and end stage renal diseases.Further, increasing geriatric population and rising wearable dialysis device adoption are also projected to drive the market growth during the forecast period.

Key Points: 
  • The growth of the South and Central America and portable and wearable dialysis devices market is attributed to the growing prevalence of chronic kidney conditions and end stage renal diseases.Further, increasing geriatric population and rising wearable dialysis device adoption are also projected to drive the market growth during the forecast period.
  • Technological advancements in dialysis devices are also anticipated to accelerate the market growth in the coming years.The outbreak of the COVID-19 pandemic is estimated to have substantial impact on the portable and wearable dialysis device market.
  • Such shortage of organ transplantation might lead to adoption of wearable and portable dialysis devices, leading to growth of the market.
  • Based on product type, the South and Central America portable and wearable dialysis devices market is segmented into hemodialysis and peritoneal dialysis.

Baxter Announces U.S. FDA 510(k) Clearance of Homechoice Claria with Sharesource

Retrieved on: 
Monday, November 23, 2020
Biotechnology, Medical Supplies, Surgery, General Health, Health, FDA, Diabetes, Medical devices, Medicine, Clinical medicine, Health sciences, Adware, Renal dialysis, Claria Corporation, Malware, Spyware, APD, Peritoneal dialysis, Baxter International, Bax

Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of the Homechoice Claria automated peritoneal dialysis (APD) system with Sharesource connectivity platform.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of the Homechoice Claria automated peritoneal dialysis (APD) system with Sharesource connectivity platform.
  • Homechoice Claria offers enhanced features that facilitate added convenience for patients and clinical teams, as well as best-in-class educational companions to further simplify the PD experience.
  • This release includes forward-looking statements concerning Homechoice Claria and Sharesource, including anticipated availability and potential benefits associated with their use.
  • Baxter, Homechoice Claria, Amia, CKD&Me and Sharesource are registered trademarks of Baxter International Inc.
    2 Firanek C. et al, Discrepancy between prescribed and actual APD prescription delivery: Identification using cycler remote management technology.